Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 3/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29792971 | 0.78 | MEN1 (0.41) | PDE4APDE4DPDE4BPDE4CCYP1A2 | |
| SCHEMBL1795561 | 0.75 | UBA6 (0.48) | — | |
| SCHEMBL19509704 | 0.75 | PRMT6 (0.42) | PDE4APDE4DPDE4BPDE4CCYP1A2 | |
| SCHEMBL29772230 | 0.75 | PRMT6 (0.42) | PDE4APDE4DPDE4BPDE4CCYP1A2 | |
| SCHEMBL19500434 | 0.75 | PRMT6 (0.42) | PDE4APDE4DPDE4BPDE4CCYP1A2 | |
| SCHEMBL17363565 | 0.75 | P2RY12 (0.34) | PDE4APDE4DPDE4BPDE4CCYP1A2 | |
| SCHEMBL17363566 | 0.75 | P2RY12 (0.34) | PDE4APDE4DPDE4BPDE4CCYP1A2 | |
| SCHEMBL25966452 | 0.75 | PRMT6 (0.42) | PDE4APDE4DPDE4BPDE4CCYP1A2 | |
| SCHEMBL29827355 | 0.74 | PRMT6 (0.41) | PDE4APDE4DPDE4BPDE4CCYP1A2 | |
| SCHEMBL9407326 | 0.74 | PRMT6 (0.40) | PDE4APDE4DCYP1A2HTR1ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190185511-A1 | LOCKED NUCLEIC ACID CYCLIC DINUCLEOTIDE COMPOUNDS AND USES THEREOF | Aduro Biotech, Inc. (US) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185511-A1 | LOCKED NUCLEIC ACID CYCLIC DINUCLEOTIDE COMPOUNDS AND USES THEREOF | STING1, TLR9, IFNAR1 | PDE4A 200/4885PDE4D 265/4885PDE4B 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.